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Abstract Five inhibitors (PLI-I^V) against Trimeresurus fla-
voviridis (Tf, habu snake, Crotalinae) venom phospholipase A2
(PLA2) isozymes have been isolated from its serum. PLI-I, which
is composed of two repeated three-finger motifs, and PLI-IV and
PLI-V, which contain a sequence similar to the carbohydrate
recognition domain (CRD) of C-type lectins, were expressed in
the forms fused with glutathione S-transferase (GST). The
resulting GST-PLIs showed ability to bind to three Tf venom
PLA2 isozymes. The binding study with the truncated forms
indicated that one of two three-finger motifs of PLI-I was able to
bind to PLA2 isozymes. The N-terminal 37-amino acid fragment
and the CRD-like domain of PLI-IV and PLI-V were bound to
PLA2 isozymes. On the other hand, their C-terminal 12-amino
acid segment also associated with PLA2 isozymes. When either
of two units of a hydrophobic tripeptide in this sequence was
replaced by trialanine, the binding was completely abolished,
indicating that the C-terminal hydrophobic cores of PLI-IV and
PLI-V were critically responsible for the binding to venom PLA2
isozymes.
z 1998 Federation of European Biochemical Societies.
Key words: Snake venom phospholipase A2 isozyme;
Serum phospholipase A2 inhibitor; Three-¢nger motif ;
Carbohydrate recognition domain; Binding study
1. Introduction
Phospholipase A2 (PLA2, EC 3.1.1.4), which is one of the
major enzymes and often forms an isozyme family in snake
venoms, catalyzes the hydrolysis of the 2-acyl ester bond of 3-
sn-phosphoglycerides to produce fatty acids and lysophospho-
lipids. Snake venom PLA2s are known to exhibit a variety of
physiological functions [1^5]. PLA2 inhibitors (PLIs), proteins
capable of inhibiting snake venom PLA2s, have been isolated
from various snake sera and their primary structures have
been determined [6^12]. PLIs can be divided into two groups
based on their structural characteristics. One group contains a
segment similar to the carbohydrate recognition domain
(CRD) of Ca2-dependent (C-type) lectins [13,14] and the
other has two repeats of a unit termed the three-¢nger motif
[11], which has also been found in urokinase-type plasmino-
gen activator receptor [15], ly-6 [16], CD59 [17] and neuro-
toxins [18].
Five Trimeresurus £avoviridis (Tf, habu snake, Crotalinae)
serum proteins, named PLI-I^V, that bind to its venom PLA2
isozymes were obtained through a⁄nity chromatography [9].
They are all glycoproteins [9]. PLI-I is a major component of
inhibitory proteins against three Tf venom basic PLA2 iso-
zymes, that is, PLA-B (a basic [Asp49]PLA2) (Y. Yamaguchi,
unpublished) and BPI [19] and BPII [20] (both [Lys49]PLA2s),
and is composed of two units of the three-¢nger motif. The
functions of three-¢nger motifs in di¡erent proteins appear to
di¡er from one another [21^23]. PLI-IV and PLI-V [7] are
known to bind to a major [Asp49]PLA2 [24], termed PLA2,
which is less basic than PLA-B. They are similar in sequence
and have a CRD-like domain [7]. Recently, we cloned cDNAs
and genes encoding PLI-I [9], PLI-VI and PLI-V [25] and
determined their nucleotide sequences. Exons 3 of genes en-
coding PLI-IV and PLI-V are exceptionally abundant in non-
synonymous nucleotide substitutions causing amino acid
changes.
The mutagenesis study of erabutoxin a, a neurotoxin from
Laticauda semifasciata venom, with a three-¢nger motif re-
vealed that V10 amino acid residues involved in three loops
are functionally important for the binding to acetylcholine
receptors [26,27]. To date, however, there is no structural in-
formation in terms of the interactions between the three-¢nger
motif and PLA2. The CRD was originally de¢ned as a func-
tional unit in C-type lectins responsible for the binding to
carbohydrate [13,14]. PLA2 receptors were isolated from var-
ious mammalian tissues [28^31] and their structural similarity
to mannose receptors was noted because they have eight tan-
dem repeats of CRDs which involve the cysteine and trypto-
phan residues at conserved positions [29]. PLA2 receptors can
bind pancreatic group I PLA2 and secretory group II PLA2
which are not glycosylated [28,31]. Although interactions oc-
cur between the CRD-like domain of PLA2 receptors and
PLA2 [30], little is known about the particular region of the
CRD-like domain which is responsible for the binding to
PLA2.
The present study was focused on the three-¢nger motifs of
PLI-I and the CRD-like domain of PLI-VI and PLI-V to
determine the structural elements required for the binding to
Tf venom PLA2 isozymes. For this purpose, these serum in-
hibitors and their truncated forms were expressed as gluta-
thione S-transferase (GST)-fused proteins or peptides in Es-
cherichia coli. The interactions between GST-fused proteins or
peptides and PLA2 isozymes immobilized on magnetic beads
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were assessed by means of in vitro immunoblot analysis using
anti-GST antibody.
2. Materials and methods
The DNA encoding full-length PLI-I was ampli¢ed by polymerase
chain reaction (PCR) of its cloned cDNA and inserted into a GST
gene-fused vector, pGEX4T-1 (Pharmacia), at EcoRI sites. The PCR-
ampli¢ed DNA, which encodes the fragment of positions 96^181 of
PLI-I, termed I(96^181), was inserted into EcoRI or BamHI/EcoRI
sites of the pGEX4T-1 vector. DNAs encoding full-length PLI-IV and
PLI-V were ampli¢ed by PCR of their cloned cDNAs and inserted
into the pGEX4T-1 vector at EcoRI sites. The DNA fragments en-
coding IV(38^147), IV(38^84), IV(38^126) and IV(127^147) which are
common in sequence between PLI-IV and PLI-V were cloned into the
pGEX4T-1 vector at EcoRI or BamHI/EcoRI sites. Synthetic oligo-
nucleotides encoding IV(1^13), IV(127^135) and IV(136^147) which
are also identical between PLI-IV and PLI-V were cloned into the
pGEX4T-1 vector at BamHI/EcoRI sites. The DNA fragments encod-
ing IV(1^37), V(1^37), IV(14^37) and V(14^37) in which amino acid
substitutions occur between PLI-IV and PLI-V were prepared by PCR
and ligated into the pGEX4T-1 vector at EcoRI or BamHI/EcoRI
sites. A mutant of IV(136^147) carrying trialanine in place of Val-
Leu-Leu at positions 137^139, represented as IV(136^
147:137AAA139), was produced by introducing the corresponding
synthetic oligonucleotide into the pGEX4T-1 vector at BamHI/EcoRI
sites. IV(136^147:143AAA145) with trialanine instead of Phe-Tyr-Phe
was also prepared.
E. coli DH5K harboring expression plasmid was incubated over-
night at 37‡C in 5 ml L-broth medium containing 100 Wg/ml ampicil-
lin. The culture was inoculated into 200 ml L-broth or Terri¢c broth
medium and incubated at 37‡C for 3 h. Isopropyl-L-D-thiogalactopyr-
anoside (0.1 mM concentration) was added to the medium and incu-
bation was continued at 25‡C for 12 h. The cells were collected by
centrifugation, resuspended in 20 mM Tris-HCl (pH 8.0) containing
150 mM NaCl and 0.1% Nonidet P-40 and sonicated with a Branson
Soni¢er Model 200 (Danbury). After centrifugation, the supernatant
was applied onto a glutathione-Sepharose 4B column with the same
bu¡er. The matrix was collected by centrifugation and washed four
times with 20 mM Tris-HCl (pH 8.0) containing 100 mM NaCl and
0.1% Nonidet P-40. The fusion protein bound to the matrix was
eluted with 20 mM Tris-HCl (pH 8.0) containing 150 mM NaCl
and 10 mM reduced glutathione.
To study the interaction of PLA2 isozymes with GST-fused PLIs
and their fragments, each of the PLA2 isozymes was conjugated
chemically to magnetic beads (MPG Long Chain Alkylamino, CPG)
according to the manufacturer’s protocol. Three Tf venom PLA2 iso-
zymes, PLA2, BPI and BPII, were fractionated from its lyophilized
crude venom via three successive chromatographies [19,20,25]. Mag-
netic beads were pretreated in 5% glutaraldehyde and 10 mM phos-
phate bu¡er (pH 7.5) for 1.5 h at room temperature. After washing
the beads (1.5 mg) ¢ve times with 10 mM phosphate bu¡er (pH 7.5),
PLA2 isozyme (200 Wg) was added and incubated at 4‡C for 1.5 h in
10 mM phosphate bu¡er (pH 7.5) containing 0.02% NaCNBH3 (total
1.0 ml). After removal of the supernatant, the beads were further
incubated in 10 mM phosphate bu¡er (pH 7.5) containing 0.02%
NaCNBH3 and 0.75% glycine for 1 h at 4‡C and then washed ¢ve
times with 10 mM phosphate bu¡er (pH 7.5) containing 1 M NaCl.
The GST-fused proteins and their fragments were incubated with
PLA2-conjugated beads in 20 mM Tris-HCl (pH 7.5) containing 100
mM NaCl and 0.5% bovine serum albumin for 1.5 h at room temper-
ature. The beads were then washed four times with the same bu¡er
containing 0.1% Nonidet P-40 to remove unbound proteins. The pro-
teins liberated from the enzyme-conjugated beads with 0.1 M acetic
acid were run on 12.5% SDS-PAGE under reducing condition and
transferred onto PVDF membrane. The membrane was incubated in
25 mM Tris-HCl (pH 7.6) containing 500 mM NaCl, 0.05% Tween-
20, 0.05% NaN3 and 5% non-fat dry milk for 1.5 h at room temper-
ature. The membrane was then treated with anti-GST monoclonal
antibody (a generous gift from Dr. Hideki Sumimoto of Kyushu
University) in the same bu¡er for 1 h at room temperature. After
washing three times with the bu¡er without dry milk, the membrane
was stained with alkaline phosphatase-conjugated anti-IgG anti-
body.
3. Results and discussion
After puri¢cation of Tf serum PLI-I^V, the nucleotide se-
quences of three cDNAs encoding PLI-I, PLI-IV and PLI-V
were determined [9,25]. For assay of the interactions between
Tf serum PLIs and its venom PLA2 isozymes, PLI-I, PLI-IV
and PLI-V were expressed in E. coli as GST-fused proteins.
GST-fused PLIs bound to PLA2, BPI and BPII immobilized
on magnetic beads were detected by anti-GST monoclonal
antibody as described in Section 2. Magnetic beads alone
did not show any a⁄nity to GST-fused PLIs (data not
shown). GST-fused PLI-I, PLI-IV and PLI-V were bound to
three PLA2 isozymes, PLA2, BPI and BPII (Figs. 1 and 2).
No binding occurred for GST alone. When an excess amount
of non-conjugated PLA2, for example, was added, GST-fused
PLIs failed to bind to conjugated PLA2 (data not shown),
indicating that the binding between immobilized PLA2 iso-
zymes and GST-fused PLIs is speci¢c. The binding modes
to BPII of all the proteins and peptides tested here were iden-
tical to those to BPI (or PLA2), so that all the data for BPII
are omitted hereafter except in Fig. 1.
Our previous study indicated that each of PLA2 isozymes
forms complex with plural di¡erent PLIs [9]. The present re-
sults showed that one inhibitor protein alone can interact
directly with each of PLA2 isozymes. Although native PLI-I,
PLI-IV and PLI-V are glycoproteins, GST-fused PLIs ex-
pressed in E. coli have no carbohydrate. However, recombi-
nant PLIs can interact with PLA2 isozymes, so that the car-
bohydrate moiety of PLI-I, PLI-IV and PLI-V is not
necessarily crucial for recognition of PLA2 isozymes.
For evaluation of the binding abilities of PLI-I segments,
they were expressed as GST-fused forms in E. coli. A segment
containing one of two three-¢nger motifs of PLI-I, I(96^145),
was e¡ectively bound to PLA2, BPI and BPII (Fig. 1). This
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Fig. 1. Binding of PLI-I and its C-terminal half to venom PLA2 iso-
zymes. A: Electrophoretograms of GST-fused PLI-I (GST-I(1^181))
(lane 1) and GST-I(96^181) (lane 2) on 12.5% SDS-PAGE. Stained
with Coomassie brilliant blue. B: In vitro binding of GST-I(1^181)
and GST-I(96^181) to PLA2 isozymes, PLA2 (lanes 1^3), BPI
(lanes- 4-6) and BPII (lanes 7^9), which had been immobilized on
magnetic beads. The GST-fused proteins bound to each of PLA2
isozymes were eluted from the a⁄nity column, subjected to SDS-
PAGE, transferred onto PVDF membrane, treated with anti-GST
monoclonal antibody and stained with alkaline phosphatase-conju-
gated anti-IgG antibody. GST alone was used as control. Lanes 1,
4 and 6, GST-I(1^181); lanes 2, 5 and 8, GST-I(96^181); lanes 3, 6
and 9, GST. The mobilities of molecular size markers are indicated
on the left in kDa.
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suggests that only one three-¢nger motif of PLI-I is capable of
binding to PLA2 isozymes.
Various fragments of PLI-IV and PLI-V were prepared in
order to identify the region required for the binding to PLA2
isozymes. The amino acid sequences of PLI-IV and PLI-V are
highly identical except for the region encoded by exon 3 [25].
The fragments containing this variable region, IV(1^37) and
V(1^37), e¡ectively interacted with PLA2 isozymes (Fig. 2).
When this region was divided into two fragments, IV(1^13)
and V(1^13) with identical sequences exhibited considerably
reduced binding activity whereas no binding was observed for
IV(14^37) and V(14^37) which contain the variable region
(Fig. 3). These results clearly indicate that the full portion
of N-terminal 37 amino acid residues of PLI-IV and PLI-V
is essential for interacting with PLA2 isozymes.
IV(38^147), which contains a sequence similar to CRDs of
some mammalian cellular PLA2 receptors, was found to bind
to PLA2 isozymes (Fig. 2). This is in accord with the fact that
the CRD-like domain of PLA2 receptors is bound to certain
PLA2s [28,30,31]. To identify the particular region involved in
the binding, several fragments of the CRD-like domain of
PLI-IV and PLI-V were prepared. A positive interaction
was detected for IV(127^147), the C-terminal portion of
PLI-IV or PLI-V (Fig. 2). On the other hand, the fragments
from the CRD-like domain in which the C-terminal region
(positions 127^147) is not involved, that is, IV(38^84) and
IV(38^126), failed to interact with any of the PLA2 isozymes
(Fig. 2). When IV(127^147) was divided into IV(127^135) and
IV(136^147), strong binding was observed for IV(136^147)
(Fig. 3), indicating that the C-terminal segment of positions
136^147 of PLI-IV or PLI-V is critically important for inter-
acting with PLA2 isozymes. This sequence, (Asn/Lys)136-Leu-
Leu-Val-Val-Cys-Glu-Phe-Tyr-Phe-Ile-Leu147, is particularly
rich in hydrophobic amino acid residues. Recently, pentapep-
tides with the sequence of Xxx-Val-Leu-Leu-Yyy (Xxx and
Yyy are any amino acid residues) were found to bind to
PLA2 isozymes (T. Chiwata, unpublished). A similar se-
quence, (Asn/Lys)-Leu-Leu-Val-Val, is noted in the above se-
quence (positions 136^141). The importance of two extremely
hydrophobic tripeptide regions, Leu-Leu-Val (positions 137^
140) and Phe-Tyr-Phe (positions 143^145), of PLI-IV and
PLI-V was then assessed. GST-fused mutants of IV(136^
147) in which these tripeptide segments were replaced by tri-
alanine, namely IV(136^147:137AAA139) and V(136^
147:143AAA145), were synthesized. The experiment showed
that the binding capacity was completely lost by these replace-
ments (Fig. 3). These results emphasize the importance of the
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Fig. 3. Binding of the C-terminal peptides of PLI-IV and PLI-V to
PLA2 isozymes. A: Electrophoretograms of GST-IV(136^
147:137AAA139) (lane 1) and GST-IV(136^147:143AAA145) (lane
2) on 12.5% SDS-PAGE. B: In vitro binding of GST-IV(135^147),
GST-IV(136^147:137AAA139), GST-IV(136^147:143AAA145) and
GST to PLA2 isozymes, PLA2 (lanes 1^4) and BPI (lanes 5^8),
which had been immobilized on magnetic beads. The binding was
detected in the same manner as described in the legend to Fig. 1.
Lanes 1 and 5, GST-IV(136^147); lanes 2 and 6, GST-IV(136^
147:137AAA139); lanes 3 and 7, GST-IV(136^147:143AAA145);
lanes 4 and 8, GST.
Fig. 2. Assay of the binding regions of PLI-IV and PLI-V to PLA2
isozymes. A: Electrophoretograms of GST-fused proteins and pep-
tides on 12.5% SDS-PAGE. B: In vitro binding of PLI-I, PLI-V
and their fragments to PLA2 which had been immobilized on mag-
netic beads. The binding was detected in the same manner as
described in the legend to Fig. 1. Lanes 1 and 9, GST-IV(1^147);
lane 2, GST-IV(1^37); lane 3, GST-IV(1^13); lane 4, GST-IV(14^
37); lane 5, GST-V(1^147); lane 6, GST-V(1^37); lane 7, GST-
V(14^37); lanes 8 and 16, GST; lane 10, GST-IV(38^147); lane 11,
GST-IV(38^126); lane 12, GST-IV(38^84); lane 13, GST-IV(127^
135); lane 14, GST-IV(136^147); lane 15, GST-IV(127^147). C: In
vitro binding of PLI-I, PLI-V and their fragments to BPI which
had been immobilized on magnetic beads. The proteins and peptides
employed and the lane numbering are exactly the same as in B. The
binding modes to BPII of all the proteins and peptides tested here
were identical to those to BPI (or PLA2), so that all the data for
BPII are omitted hereafter.
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C-terminal segment of PLI-IV and PLI-V for association to
PLA2 isozymes. The structural units of PLI-I and of PLI-IV
and PLI-V and the binding capacities of their segments to
PLA2 isozymes are summarized in Fig. 4.
A recent study showed that the pentapeptide from positions
70^74 of three group II PLA2s inhibits its own PLA2 activity
in mixed micelles [32]. This segment is involved in a L-loop of
this molecule which is in contact with its N-terminal region by
hydrogen bonding [33]. The properties of the pentapeptide
constituting positions 70^74 of Tf PLA2 isozymes and other
three group II PLA2s are di¡erent from those of peptides
constituting the C-terminal hydrophobic region of PLI-IV
and PLI-V, indicating that the mechanism of inhibition of
PLA2s di¡ers between peptides derived from the L-loop seg-
ment of PLA2 itself and peptides from the C-terminal hydro-
phobic region of PLI-IV and PLI-V.
The present study ignored the roles of the disul¢de bonds of
the three-¢nger motif and the CRD-like domain of inhibitors.
The data, therefore, show that E. coli-expressed PLI-I, PLI-IV
and PLI-V and some of their segments have a⁄nities to ven-
om PLA2 isozymes strong enough to make a stable and iso-
latable complex. If they have any proper disul¢de bonds, it is
likely that their a⁄nities must be strengthened.
As mentioned, the hydrophobic core of the C-terminal re-
gion of PLI-IV and PLI-V is critical for binding to PLA2
isozymes. It was noted that the C-terminal 12 amino acid
residues of PLI-IV are identical to those of PLI from Agkis-
trodon blomho⁄i siniticus serum [10], implying that the CRD-
like domain in snake serum PLIs is one of the essential struc-
tural elements to recognize PLA2 isozymes. Since CRDs of
PLA2 receptors do not have such a hydrophobic core in their
C-terminal regions [28^31], it is likely that the binding of the
C-terminal region of PLI-IV and PLI-V to PLA2 isozymes is
mechanistically di¡erent from the binding of PLA2 receptors
to PLA2. It was found that a pentapeptide Ser-Phe-Tyr-Phe-
Trp, which is similar in property to the C-terminal region of
PLI-IV and PLI-V, inhibit PLA2 in a dose-dependent manner
(T. Chiwata, unpublished). This strongly suggests that the C-
terminal region of PLI-IV and PLI-V actually inhibits PLA2
activity through the binding to the active site cleft or its vi-
cinity of PLA2 isozymes. It is conceivable that GST-fused
PLIs not only bind to PLA2 isozymes but also inhibit their
activity.
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